{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"萌喵读文献-肿瘤学","title":"今日肿瘤学最高分文献 - 2024-10-29","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/af6429b4\"></iframe>","width":"100%","height":180,"duration":4,"description":"欢迎收听今天的医学播客！最新研究发现，对于被认为不适合铂类化疗的晚期尿路上皮癌患者，一线单药疗法pembrolizumab显示出一致的抗肿瘤活性和安全性。这项分析汇总了KEYNOTE-052和LEAP-011研究中可能不适合铂类化疗的患者，包括不同标准的患者群体。结果显示，客观反应率、无进展生存期和总生存期在各组中均具有一致性，治疗相关不良事件率也在各组间保持一致。这一发现为这些患者提供了新的治疗选择，具有重要的临床意义。想了解更多细节吗？敬请关注我们的深入报道。","thumbnail_url":"https://img.transistorcdn.com/3WX36CzvFOrNjlF7WfWjzS4HdcMIMmzMs2bmPS-ejLU/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS83NDNm/MjQ1N2E5NjhjMzVj/NjM0ZTA3YzY2NDE2/ZmIyMi5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}